MMA
IBRX icon

Miracle Mile Advisors’s ImmunityBio IBRX Stock Holding History

Miracle Mile Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Hold
21,650
– – ﹤0.01% 975
2026
Q1 		$166K Sell
21,650
-100
-0.5% -$685 ﹤0.01% 863
2025
Q4 		$43.1K Sell
21,750
-14,950
-41% -$33.9K ﹤0.01% 862
2025
Q3 		$90.3K Buy
36,700
+7,845
+27% +$20.2K ﹤0.01% 813
2025
Q2 		$76.2K Buy
+28,855
New +$77.6K ﹤0.01% 711

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Miracle Mile Advisors's IBRX Position: Q2 2026 in Review

Miracle Mile Advisors held its ImmunityBio (IBRX) position steady in Q2 2026 at 21,650 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #975.

Miracle Mile Advisors first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Miracle Mile Advisors held 21,650 shares of ImmunityBio worth $190K as of Q2 2026.
  • Miracle Mile Advisors left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Miracle Mile Advisors's portfolio in Q2 2026, its #975 holding.
  • Miracle Mile Advisors first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Miracle Mile Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.